- Home
- ATYR vs ALLT Comparison
ATYR vs ALLT Comparison
Compare ATYR & ALLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- ALLT
- Stock Information
- Founded
- ATYR 2005
- ALLT 1996
- Country
- ATYR United States
- ALLT Israel
- Employees
- ATYR N/A
- ALLT N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- ALLT Telecommunications Equipment
- Sector
- ATYR Health Care
- ALLT Telecommunications
- Exchange
- ATYR Nasdaq
- ALLT Nasdaq
- Market Cap
- ATYR 105.8M
- ALLT 458.2M
- IPO Year
- ATYR 2015
- ALLT 2006
- Fundamental
- Price
- ATYR $0.97
- ALLT $9.73
- Analyst Decision
- ATYR Buy
- ALLT Strong Buy
- Analyst Count
- ATYR 6
- ALLT 3
- Target Price
- ATYR $8.88
- ALLT $12.75
- AVG Volume (30 Days)
- ATYR 8.3M
- ALLT 404.0K
- Earning Date
- ATYR 11-11-2025
- ALLT 11-18-2025
- Dividend Yield
- ATYR N/A
- ALLT N/A
- EPS Growth
- ATYR N/A
- ALLT N/A
- EPS
- ATYR N/A
- ALLT N/A
- Revenue
- ATYR N/A
- ALLT $95,342,000.00
- Revenue This Year
- ATYR $420.85
- ALLT $10.44
- Revenue Next Year
- ATYR $1,513.40
- ALLT $12.99
- P/E Ratio
- ATYR N/A
- ALLT N/A
- Revenue Growth
- ATYR N/A
- ALLT 4.74
- 52 Week Low
- ATYR $0.68
- ALLT $3.35
- 52 Week High
- ATYR $7.29
- ALLT $11.42
- Technical
- Relative Strength Index (RSI)
- ATYR 32.21
- ALLT 51.07
- Support Level
- ATYR $0.94
- ALLT $9.84
- Resistance Level
- ATYR $1.02
- ALLT $10.69
- Average True Range (ATR)
- ATYR 0.08
- ALLT 0.47
- MACD
- ATYR 0.12
- ALLT -0.06
- Stochastic Oscillator
- ATYR 32.23
- ALLT 53.59
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About ALLT Allot Ltd.
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.